Insider Selling: Furiex Pharmaceuticals VP Unloads 45,691 Shares of Stock (FURX)
Furiex Pharmaceuticals (NASDAQ:FURX) VP Paul S. Covington sold 45,691 shares of the stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $104.11, for a total transaction of $4,756,890.01. Following the completion of the sale, the vice president now directly owns 22,523 shares of the company’s stock, valued at approximately $2,344,870. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Furiex Pharmaceuticals (NASDAQ:FURX) remained flat at $104.25 during during mid-day trading trading on Friday. 182,129 shares of the company’s stock traded hands. Furiex Pharmaceuticals has a 52-week low of $32.05 and a 52-week high of $121.97. The stock’s 50-day moving average is $104.2 and its 200-day moving average is $80.37. The company’s market cap is $1.126 billion.
Furiex Pharmaceuticals (NASDAQ:FURX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($1.25) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.63) by $0.62. The company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $10.01 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was down 83.7% on a year-over-year basis. On average, analysts predict that Furiex Pharmaceuticals will post $-2.27 earnings per share for the current fiscal year.
Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.